CorMedix is transitioning from a launch-driven story centered on its catheter lock solution DefenCath into a broader test of commercial durability, portfolio integration, and reimbursement execution. DefenCath, the first and only FDA-approved antimicrobial catheter lock solution in the U.S., generated first-quarter 2026 net revenues of $97.5 million and has multi-year agreements covering roughly 60% of the U.S. outpatient dialysis market. The August 2025 acquisition of Melinta Therapeutics added six marketed infectious disease products and Toprol-XL, contributing $45.5 million in revenues in 2025 after the deal closed and $29.9 million in the first quarter of 2026, with expected annual cost synergies of $35 million to $45 million. Within the Melinta portfolio, Rezzayo is seen as the most important growth option, with a current treatment market estimated at $250 million to $350 million and a potential prophylaxis indication targeting a U.S. market of more than $2 billion following positive phase III ReSPECT study results. However, DefenCath faces a significant reimbursement decline starting July 1, 2026, as it moves to the post-adjustment add-on phase, which is expected to reduce net pricing in the second half of the year and create uneven quarterly revenues. The stock carries a Zacks Rank #3 (Hold) with Value, Growth, Momentum, and VGM Scores all of A, indicating strong characteristics across valuation, growth, and momentum but suggesting the earnings revision picture is not yet strong enough for a more aggressive call.
CorMedix IncDefenCath multi-year agreements covering 60% of U.S. outpatient dialysis market and Q1 2026 revenues of $97.5M
Baxter International Inc
Pfizer Inc